Alpha-MSH and KPV Kill Drug-Resistant Bacteria Including MRSA

What the researchers found

Alpha-MSH and KPV demonstrated broad-spectrum antimicrobial activity including against MRSA and drug-resistant organisms, with an anti-Candida mechanism resembling amphotericin B membrane disruption.

Why it matters

Drug-resistant infections kill over a million people annually. A tiny, easily synthesized peptide that kills MRSA and other resistant organisms could become a valuable addition to the antimicrobial arsenal.

How the study worked

In-vitro antimicrobial study testing alpha-MSH and KPV against expanded panels of gram-positive, gram-negative bacteria, and fungi using MIC/MBC determinations and mechanistic candidacidal assays.

What this study cannot tell us

In-vitro activity. Concentrations required may exceed physiological levels. In-vivo efficacy not tested. The extremely small size of KPV could affect pharmacokinetics.

How to read the evidence

Moderate in-vitro evidence with expanded pathogen panel including clinically relevant drug-resistant strains and mechanistic characterization.

When this study was published

Published in 2000. KPV's antimicrobial properties have contributed to growing interest in this peptide for gut and skin therapeutic applications.

The bigger picture

The antimicrobial resistance crisis needs new drug classes. KPV represents an entirely different approach — a tiny peptide fragment from the body's own immune system that kills resistant organisms through fundamental membrane mechanisms.

Questions still open

• Can KPV achieve antimicrobial concentrations in vivo?
• Would bacteria develop resistance to KPV?
• Could KPV be developed as a topical antibiotic for skin infections?

Common questions

Read the original research

Antimicrobial effects of alpha-MSH peptides.

Journal of leukocyte biology, 67(2), 233-9

Citation

Cutuli, M; Cristiani, S; Lipton, J M; Catania, A. (2000). Antimicrobial effects of alpha-MSH peptides.. Journal of leukocyte biology, 67(2), 233-9.